Glial Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration by María I. Herrera et al.
fnagi-08-00081 April 23, 2016 Time: 12:12 # 1
MINI REVIEW
published: 26 April 2016
doi: 10.3389/fnagi.2016.00081
Edited by:
Jean Mariani,
Universite Pierre et Marie Curie,
France
Reviewed by:
Diego Ruano,
University of Sevilla, Spain
Adelaide Fernandes,
University of Lisbon, Portugal
Caterina Scuderi,
Sapienza University of Rome, Italy
*Correspondence:
Francisco Capani
franciscocapani@hotmail.com
Received: 11 December 2015
Accepted: 30 March 2016
Published: 26 April 2016
Citation:
Herrera MI, Kölliker-Frers R,
Barreto G, Blanco E and Capani F
(2016) Glial Modulation by
N-acylethanolamides in Brain Injury
and Neurodegeneration.
Front. Aging Neurosci. 8:81.
doi: 10.3389/fnagi.2016.00081
Glial Modulation by
N-acylethanolamides in Brain Injury
and Neurodegeneration
María I. Herrera1,2, Rodolfo Kölliker-Frers1, George Barreto3, Eduardo Blanco4 and
Francisco Capani1,5,6,7*
1 Instituto de Investigaciones Cardiológicas, Facultad de Medicina, Universidad de Buenos Aires – Consejo Nacional de
Investigaciones Científicas y Técnicas, Buenos Aires, Argentina, 2 Centro de Investigaciones en Psicología y Psicopedagogía,
Facultad de Psicología, Universidad Católica Argentina, Buenos Aires, Argentina, 3 Department of Nutrition and
Biochemistry, Faculty of Sciences, Pontificia Universidad Javeriana, Bogotá, Colombia, 4 Departament de Pedagogia i
Psicologia, Facultat d’Educació, Psicologia i Treball Social, Universitat de Lleida, Lleida, Spain, 5 Facultad de Psicología,
Universidad Católica Argentina, Buenos Aires, Argentina, 6 Departamento de Biología, Universidad Argentina John F.
Kennedy, Buenos Aires, Argentina, 7 Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad
Autónoma de Chile, Santiago, Chile
Neuroinflammation involves the activation of glial cells and represents a key element
in normal aging and pathophysiology of brain damage. N-acylethanolamides (NAEs),
naturally occurring amides, are known for their pro-homeostatic effects. An increase
in NAEs has been reported in vivo and in vitro in the aging brain and in brain injury.
Treatment with NAEs may promote neuroprotection and exert anti-inflammatory actions
via PPARα activation and/or by counteracting gliosis. This review aims to provide an
overview of endogenous and exogenous properties of NAEs in neuroinflammation and
to discuss their interaction with glial cells.
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INTRODUCTION
Brain injury includes several conditions that damage the brain and alter its function, such as
trauma, stroke, hypoxia, and infection. Although this term generally refers to sudden insults,
neurodegenerative disorders are also sources of brain damage (Lukersmith et al., 2016). There
are still no effective treatments for most cases of brain injury and numerous gaps regarding
their physiopathology. However, research has elucidated the possible detrimental effects of the
inflammatory response mediated by glial cells. If this response is uncontrolled and chronic, it
may lead to neurotoxicity (Arevalo et al., 2012) and disruption of endogenous neurogenesis
(Whitney et al., 2009). This phenomenon known as neuroinflammation is also evident in the
aging brain, which is particularly vulnerable to neurodegenerative and neuropsychiatric disease
(Matt and Johnson, 2016; Mohan et al., 2016). Therefore, neuroinflammation is a key target for
neuroprotection and repair (Skaper et al., 2013, 2014), which constitutes a promising alternative
for brain injury and neurological disorders.
N-acylethanolamides (NAEs) are endogenous lipid mediators which apparently elicit a pro-
homeostatic role in response to neuroinflammation (Esposito and Cuzzocrea, 2013; Skaper et al.,
2013). In addition, exogenous administration of NAEs could exert neuroprotective effects by
reducing neuroinflammation, as it has been demonstrated in several models of β-amyloid- induced
astrogliosis (Scuderi et al., 2011, 2012; Benito et al., 2012), Alzheimer disease (D’Agostino et al.,
2012; Scuderi et al., 2014), Parkinson disease (Galan-Rodríguez et al., 2009; Esposito et al., 2012;
González-Aparicio et al., 2014), stroke (Ahmad et al., 2012b), cerebral ischemia (Zhou et al., 2012),
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traumatic brain injury (Ahmad et al., 2012a), spinal cord injury
(SCI) (Genovese et al., 2008; Esposito et al., 2011), peripheral
neuropathy (Mannelli et al., 2013) and lipopolysaccharide (LPS)-
induced neuroinflammation (Sayd et al., 2015). The aim of this
review is to provide an overview of recent progress related
to the endogenous and exogenous neuroprotective and anti-
inflammatory properties of NAEs, emphasizing their effects on
glial cells.
ASTROCYTES, MICROGLIA, AND
NEUROINFLAMMATION
Astrocytes contribute to maintain homeostasis in the central
nervous system (CNS) by providing nutrients to neurons,
recycling neurotransmitters and regulating synaptic plasticity
(Pekny and Pekna, 2015). Astrocytes also have a critical role
in the regulation of neural immune response and neuronal
survival, promoting wound healing and tissue repair upon CNS
insults (Wang and Bordey, 2008; Jha et al., 2016). Modifications
in gene expression, hypertrophy and proliferation of astrocytes
are involved in preserving neuronal function (Sofroniew, 2005).
Microglia also responds to brain injury. It constitutes the
resident macrophage population of the CNS (Hanisch and
Kettenmann, 2007; Matt and Johnson, 2016) that migrates to
the injury site and initiates communication with the immune
system (Robel et al., 2011). While astrocytes monitor extracellular
fluid, pH and ion homeostasis in order to promote the
recovery of injured tissue, microglia scavenges dead cells, and
secretes neurotrophic factors. This process is known as reactive
gliosis (Skaper et al., 2014), and is characterized by molecular,
morphological and functional changes in glial phenotype in
response to brain injury (Zamanian et al., 2012; Pekny and Pekna,
2015).
Cytokines mediate communication between nervous and
immune system (Skaper et al., 2013, 2014), which is known
as neuroimmunomodulation (Arevalo et al., 2012). Therefore,
besides generating pro-inflammatory molecules, glial cells
respond to pro-inflammatory signals released from mast cells
(Skaper and Facci, 2012), and cytokines recruit glia to the focus of
inflammation (Dong and Benveniste, 2001; Rebenko-Moll et al.,
2006; Rostène et al., 2007).
However, if glial activation is excessive, the inflammatory
response oriented to protect neural tissue might override
the bounds of physiological control (Skaper et al., 2013,
2014) and reactive gliosis becomes dysfunctional (Pekny and
Pekna, 2015). This phenomenum called neuroinflammation
leads to neurotoxicity and promotes further injury (Arevalo
et al., 2012). While acute insults are transient and rarely
detrimental to neuronal survival, neuroinflammation is a
chronic and self-perpetuating response, which may constitute
a point of origin for neurological disorders (Jha et al.,
2016). Non-resolving inflammation is a major cause of
disease since inflammation can damage tissue and necrosis
can exacerbate inflammation (Nathan and Ding, 2010).
Moreover, uncontrolled inflammation promotes disruption of
endogenous neurogenesis (Whitney et al., 2009) and synaptic
dysfunction (Chung et al., 2015), inhibiting adaptive plasticity
mechanisms needed for functional recovery (Pekny and Pekna,
2015).
Genes mediating neuroinflammation and immune
system activation show significant age-related upregulation
(Mohan et al., 2016). Aging acts as a silent contributor to
neuroinflammation, establishing the condition as a central
pathophysiological mechanism, maintaining, and impairing it
(Sandu et al., 2015). Reactive gliosis and neuroinflammation
may be triggered by the accumulation of proteins with abnormal
conformations (e.g., β-amyloid) or by signals emanating from
brain injury processes (e.g., hypoperfusion of neural tissue) in
the aging brain (Gouw et al., 2011; Scuderi et al., 2011).
The aging brain is characterized by a sensitization to
neuroinflammatory responses, which provokes abnormalities
in brain structure and metabolism (Rosano et al., 2012).
Aged microglia is primed to be activated and resistant to
endogenous regulatory systems (Norden and Godbout, 2013).
Hence, the response of microglia to stimulus involves a
more robust and persistent production of pro-inflammatory
cytokines, which compromises normal neuronal functionality
(Boche et al., 2013; Perry and Teeling, 2013). Microglia
develops a loss of integrated regulatory networks. Therefore,
homeostasis in brain-immune interactions is considerably
altered and reduced. This neuro-immune dysfunction is
associated with a low-grade chronic neuroinflammation,
which contributes to cognitive deficits and susceptibility
to age-related pathologies (Matt and Johnson, 2016):
neurodegenerative and neuropsychiatric diseases (Mohan
et al., 2016).
Neuroinflammation represents a key element in brain aging
(Matt and Johnson, 2016; Mohan et al., 2016) and in the
pathophysiology of several neurological diseases (Skaper et al.,
2014, 2015): neurodegenerative disorders (Giovannini et al.,
2002; Dauer and Przedborski, 2003; McGeer and McGeer, 2013;
Amor et al., 2014), stroke (Iadecola and Anrather, 2011), chronic
neuropathic pain (Myer et al., 2006; Tenorio et al., 2013), among
others. Therefore, neuroinflammation constitutes an important
target for neuroprotection (Skaper et al., 2013, 2014). Although
mechanisms of neuroinflammation are probably similar in aging
and a wide range of neurological diseases, these conditions differ
in etiology and in how the inflammatory response contributes
to progressive damage. A thorough understanding of these
molecular pathways is necessary for designing neuroprotective
strategies (Sandu et al., 2015).
THE N-acylethanolamides SIGNALING
SYSTEM
N-acylethanolamides are present in human and murine brain in
considerable amounts (Di Marzo, 1998; Maccarrone and Finazzi-
Agró, 2002, 2003). NAEs are endogenous lipid mediators that
include the endocannabinoid N-arachidonoylethanolamide
(anandamide or AEA) and its congeners, the non-
cannabimimmetic compounds Palmitoylethanolamide (PEA)
and Oleoylethanolamide (OEA) (Skaper et al., 2013; Sayd et al.,
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FIGURE 1 | Structural formulas for N-acylethanolamides (NAEs).
2015) (Figure 1). AEA is synthesized by the hydrolysis of
N-acylphosphatidyletanolamide (NAPE), through the action of
the enzyme N-acylphosphatidylethanolamide-phospholipase D
(NAPE-PLD). After performing in CB1 and CB2 receptors, AEA
is degraded by the action of the enzyme fatty acid amidohydrolase
(FAAH). AEA is also synthesized from ethanolamide and a fatty
acid (arachidonic acid) (Figure 2). AEA is a transient signal
synthesized on demand, from changes in cell membrane
induced by stimulating glutamatergic, GABAergic, cholinergic,
or dopaminergic receptors. This transient signal can act as
a retrograde or anterograde messenger, either by inhibiting
neurotransmitter release on presynaptic CB1 or by controlling
postsynaptic depolarization (Piomelli, 2003; Rodríguez de
Fonseca, 2012) (Figure 2).
N-acylethanolamides share biosynthetic and degradative
mechanisms. Like AEA, PEA, and OEA are produced on demand
through NAPE-PLD and catalyzed by FAAH (Rodríguez de
Fonseca et al., 2001; Piomelli, 2003; Skaper et al., 2013; Sayd
et al., 2015). PEA and OEA can be also synthesized from
ethanolamine and a fatty acid: palmitic acid or oleic acid,
respectively (Rodríguez de Fonseca, 2012; Scuderi et al., 2014)
(Figure 2). Although PEA and OEA do not bind cannabinoid
receptors (CB1 and CB2) (Rodríguez de Fonseca et al., 2001;
Mackie and Stella, 2006; Scuderi et al., 2014; Vacondio et al.,
2015), they can act as entourage compounds, enhancing the
activity of AEA (De Petrocellis et al., 2001; Cravatt and Lichtman,
2002; Ross, 2003; Bradshaw and Walker, 2005; Re et al., 2007;
Liput et al., 2014).
The biological effects of PEA and OEA are mainly mediated
via the activation of the nuclear Peroxisome Proliferator-Activated
Receptor-alpha (PPARα) (Rodríguez de Fonseca et al., 2001; Lo
Verme et al., 2005; Sun et al., 2007). However, PEA and OEA
might act through alternative receptors: the transient receptor
potential vaniloid type-1 (TRPV1) (Van Der Stelt and Di Marzo,
2004; Wang et al., 2005; Almási et al., 2008; Thabuis et al., 2008),
the G protein-coupled receptors GPR55 and GPR119 (Overton
et al., 2006; Godlewski et al., 2009), and other peroxisome
proliferator-activated receptor (PPAR) isoforms (PPAR-δ and
PPAR-γ) (Fu et al., 2003; Paterniti et al., 2013). Although PEA and
OEA are known to exert a protective role in response to brain
injury and neuroinflammation (Esposito and Cuzzocrea, 2013),
their specific role on synapsis is still unknown (Figure 2).
Endogenous Pro-homeostatic Properties
of N-acylethanolamides
Glial cells possess endogenous homeostatic molecules, such as
NAEs, which can be up-regulated in response to harmful stimuli
provoking inflammation (Skaper et al., 2013). In vitro studies
have demonstrated that NAEs are produced by astrocytes (Walter
et al., 2002) and PEA is synthesized and hydrolysed by microglia
(Muccioli and Stella, 2008). NAEs are known to be accumulated
in mammalian tissues as a result of membrane changes associated
with necrosis (Berdyshev et al., 2000). Pronounced increases
in NAEs were reported in glutamate-induced excitotoxicity in
cultured cortical neurons (Hansen et al., 1995, 1997). These
homeostatic signals regulate cell survival upon brain damage and
neuroinflammation (Esposito and Cuzzocrea, 2013).
A release of OEA (up to 242 pmol/mL), PEA (up to
120 pmol/mL), and AEA (up to 42 pmol/mL) was reported
in vivo during human stroke, suggesting the contribution of
NAEs signaling system to downstream events in the ischemic
cascade (Schäbitz et al., 2002). A significant accumulation of
NAEs has been also observed in a murine model of stroke. Striatal
and cortical NAEs concentrations were about 30-fold higher
in the infarcted than in the non-infarcted hemisphere (Berger
et al., 2004). In addition, an augmentation in PEA levels was
observed in a murine model of focal cerebral ischemia (Franklin
et al., 2003). Moreover, an accumulation of N-acetylethanolamide
phospholipids (NAPEs) has been registered in rat brain during
post-decapitative ischemia. NAPEs are precursors for NAEs and
can be formed as a stress response during neuronal injury
(Natarajan et al., 1986). This ischemia-induced synthesis is
apparently age-dependent and more pronounced in developing
than in adult brain (Moesgaard et al., 2000).
N-acylethanolamides might also exert a pro-homeostatic role
in response to reactive gliosis and neuroinflammation in the
aging brain. Recent in vivo studies have reported increased
availability of AEA (Pascual et al., 2014) and NAPE-PLD (Di
Marzo et al., 2015) during aging. PEA and OEA are up-
regulated in activated cultured primary rat astrocytes after β-
amyloid (Aβ) accumulation (Scuderi et al., 2011), a frequent
event in the aging brain (Gouw et al., 2011). In addition,
in vitro studies have also shown an increase of PEA levels in
response to neurodegeneration and reactive gliosis in organotypic
hippocampal slice cultures (OHSCs) (Kallendrusch et al., 2010).
Endogenous synthesis of NAEs might be an adaptive
response for the down-modulation of mast cells hyperactivity
and consequent expression of pro-inflammatory molecules
(Esposito and Cuzzocrea, 2013). This mechanism is known by
the ALIA acronym (Autacoid Local Inflammation Antagonism)
(Aloe et al., 1993). Mast cells, non-neural and immune-
related cells, are capable of crossing both compromised
blood-spinal cord and blood–brain barrier in cases of CNS
pathology. However, NAEs could also protect neurons against
glutamate excitotoxicity (Skaper et al., 1996). This finding
contributed to the understanding of the pro-homeostatic
role of NAEs, which represents a broader local anti-
injury function (Autacoid Local Injury Antagonism), not
limited to an autacoid reduction of inflammation. These
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FIGURE 2 | Role of synthesis and catalysis of N-acylethanolamides (NAEs) on the synaptic transmission. Anandamide (AEA) is synthesized when
N-acylphosphatidyletanolamide (NAPE) is hydrolysed by a specific phospholipase D (PLD). AEA is also synthesized from arachidonic acid (AA) and ethanolamide.
When AA is replaced by palmitic acid (PA) or oleic acid (OA), Palmitoylethanolamide (PEA), or Oleoylethanolamide (OEA) are synthesized respectively. PA and OA are
AA conjugates with other compounds, and therefore PEA and OEA are considered as AEA derivatives. AEA contributes to bioelectrical plasticity, by acting as a
retrograde, or anterograde messenger. After performing in CB1 and CB2 receptors, AEA is catalyzed by fatty acid amidohydrolase (FAAH). FAAH is the primary
catabolic enzyme for AEA, and it also regulates the contents of PEA and OEA, which do not activate CB1 and CB2. Instead, PEA and OEA apparently activate
non-cannabinoid receptors, such as PPARα. Nevertheless, the role of PEA and OEA on synapsis is still unclear. NT, Neurotransmitter; DA, Dopamine; AC,
Acetylcholine; VGCC, Voltage-gated calcium channel; NMDA, N-Methyl-D-aspartate; GPCR, G protein–coupled receptors; PE, Phosphatidyl ethanolamine; PC,
Phosphatidylcholine; NAT, N-acetyltransferase; K+, Pottasium ion; Ca2+, Calcium ions; cAMP, Cyclic adenosine monophosphate; ATP, Adenosine triphosphate; AC,
Adenylate cyclase; GOLF, Olfactory neuron specific-G protein involved in odorant signal transduction; Gs/i, Stimulating/Inhibitory G Protein; PK activity, Protein
Kinase activity; AT, Anandamide Translocase.
ALIAmides down-regulate mast cells, protect neurons
against excitotoxicity, and inhibit the spread of necrosis,
thus preventing secondary neuronal damage (Esposito and
Cuzzocrea).
The entourage hypothesis was proposed in order to explain
a possible mechanism of PEA and OEA pro-homeostatic
properties. This hypothesis suggests that OEA and PEA inhibit
the degradation of AEA by competing with AEA for FAAH
catalytic activity, thus increasing AEA levels and cytoprotective
action (De Petrocellis et al., 2001; Cravatt and Lichtman, 2002;
Ross, 2003; Bradshaw and Walker, 2005; Re et al., 2007; Liput
et al., 2014). For instance, increases of PEA levels were reported
in early stages of SCI. This augmentation could be explained
by the entourage hypothesis: an increase in AEA levels and
down-regulation of FAAH was also registered (Garcia-Ovejero
et al., 2009). However, another mechanism was proposed for
the protective role of endogenous OEA and PEA: the activation
of a nuclear receptor such as PPARα (Esposito and Cuzzocrea,
2013). The up-regulation of PEA and OEA in activated cultured
primary rat astrocytes after Aβ accumulation elicited protective
effects through PPARα activation, possibly to antagonize the
effects of PPARα down-regulation caused by Aβ exposure. In fact,
down-modulation of PPARα may represent one of the molecular
mechanisms by which Aβ exerts its toxicity (Scuderi et al., 2011).
THERAPEUTIC ACTIVITY OF
N-acylethanolamides
Exogenous NAEs act apparently through receptor pleiotropism,
i.e., interactions with different receptor targets, such as PPARα
(Skaper et al., 2013). PPARs are known to regulate the expression
of large gene arrays, thus modulating important metabolic events
(Berger et al., 2005), innate and adaptive immunity (Daynes
and Jones, 2002). In vivo studies have reported that the anti-
inflammatory properties of PEA (Lo Verme et al., 2005) and OEA
(Sun et al., 2007) associated with neuronal protection are exerted
by activating PPARα. This anti-inflammatory effect observed
in wild-type mice was absent in mutant PPARα-deficient mice
(Lo Verme et al., 2005; Sun et al., 2007). PPARα-mediated
neuroprotection was later replicated in several models of brain
injury and neurodegeneration. Another mechanism associated
with NAEs therapeutic action is down-regulation of glial activity,
as it is described below and summarized in Table 1.
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TABLE 1 | Therapeutic effects of N-acylethanolamides (NAEs) in several in vivo and in vitro models of brain damage.
Model of brain damage Therapeutic action of OEA, PEA, or AEA Reference
Aβ-induced astrogliosis (In vitro) Reduction in TNFα, COX-2, and iNOS expression Benito et al., 2012
Model of brain damage Therapeutic action of OEA Reference
Acute cerebral ischemia (Middle cerebral
artery occlusion in mice)
Dose-dependent reduction of infarct volume and brain edema
Dose-dependent improvement in neurological dysfunction
PPARα activation
Zhou et al., 2012
Perinatal asphyxia (PA) (Water bath at 37◦C
for 20 min immediately after delivery)
Improvement in exploratory locomotion at postnatal day 30 Herrera et al., 2014
Parkinson Disease (PD) (6-OHDA-induced
striatal lesion in rats)
Dose-dependent reduction in reactive microglia activation (OX6 expression) and oxidative
response (HO-1 expression)
Galan-Rodríguez et al.,
2009
6-OHDA induced degeneration of
substantia nigra dopamine neurons (In vitro)
Dose-dependent protection against toxicity and cell death Galan-Rodríguez et al.,
2009
Parkinson Disease (6-OHDA-induced
striatal lesion in rats)
Dose-dependent reduction in neurotoxicity and oxidative response (HO-1 expression)
Dose-dependent reduction of behavioral deficits
González-Aparicio
et al., 2014
6-OHDA induced degeneration of
substantia nigra dopamine neurons (In vitro)
Dose-dependent protection against 6-OHDA-induced toxicity PPARα activation González-Aparicio
et al., 2014
Lipopolysaccharide-induced
neuroinflammation (LPS injection in rats)
Enhancement of the hypothermic response after LPS injection
Reduction in oxidative/nitrosative stress, IL-1β, COX-2, PGE2, and TNF-α mRNA expression
Disruption of anhedonia
Sayd et al., 2015
Model of brain damage Therapeutic action of PEA Reference
Lipopolysaccharide-induced
neuroinflammation (LPS injection in rats)
Enhancement of the hypothermic response after LPS injection
Reduction in oxidative/nitrosative stress, IL-1β, COX-2, and PGE2 expression
Sayd et al., 2015
Stroke (Middle cerebral artery occlusion in
rats)
Reduction of edema, brain infarction, and lesion size
Improvement in apoptosis level
Blockage of astrocytes infiltration
Reduction of motor deficits
Ahmad et al., 2012b
Traumatic brain injury (TBI) [Controlled
cortical impact (CCI) in mice]
Reduction of lesion size
Improvement in apoptosis level
Blockage of astrocytes infiltration
Improvement in neurobehavioral functions
Ahmad et al., 2012a
Spinal cord injury (SCI) (Compression
model in mice)
Reduction of tissue injury
Reduction in the degree of apoptosis and pro-inflammatory cytokine expression
Recovery of motor limb function
PPARα activation
Genovese et al., 2008
Spinal cord injury (Compression model in
mice)
Reduction in mast cell infiltration and activation
Reduction in activation of microglia and astrocytes expressing CB2
Changes in the expression of neurotrophic factors and in spinal cord dopaminergic function
Esposito et al., 2011
Peripheral neuropathy [Chronic constriction
injury (CCI) in mice]
Reduction of edema
Reduction in macrophage infiltration
Augmentation in myelin sheath and axonal diameter
Anti-nociception
PPARα activation
Mannelli et al., 2013
Alzheimer Disease (AD) (Aβ peptide
injection in mice)
Reduction in lipid peroxidation, protein nytrosylation, iNOS induction, and caspase 3 activation
expression
Dose-dependent reduction or prevention of learning and memory impairment
PPARα activation
D’Agostino et al., 2012
Alzheimer Disease (Aβ peptide injection in
rats)
Reversion of reactive gliosis, amyloidogenesis, and tau protein hyperphosphorylation
Reduction of mnestic deficits
PPARα activation
Scuderi et al., 2014
Aβ-induced astrogliosis (In vitro) Reduction in astrocytes activation
Improvement in neuronal survival
PPARα activation
Scuderi et al., 2012
Aβ-induced astrogliosis (In vitro) Reduction in iNOS, COX-2, nitric oxide, IL-1β, TNF-α, and PGE2 expression
PPARα activation
Scuderi et al., 2011
Parkinson Disease (MPTP injection in mice) Protection against neurotoxicity and the ensuing functional deficits, loss of TH positive
neurons, and alterations of microtubule-associated protein 2a,b, dopamine transporter and
nNos-positive cells
Reduction in microglial activation and the number of GFAP-positive astrocytes
Reversion of motor deficits
PPARα activation
Esposito et al., 2012
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Neuroprotection in Experimental Models
of Brain Injury
Oral OEA pre-treatment (10, 20, and 40 mg/kg, for 3 days
before ischemia) could exert neuroprotective effects against
acute cerebral ischemic injury in mice. Transient focal cerebral
ischemia was induced by middle cerebral artery occlusion
(MCAo) for 90 min followed by reperfusion. OEA pre-treatment
was associated with an improvement in neurological dysfunction
and a reduction in infarct volume and brain edema. This
effect was exerted via PPARα in a dose-dependent manner
with 40 mg/kg as the most effective dose (Zhou et al.,
2012). In addition, administration of OEA (10 mg/kg) in rats
subjected to perinatal asphyxia (PA) was associated with an
improvement in exploratory locomotion at postnatal day 30. PA
was induced by a water bath at 37◦C for 20 min immediately
after delivery. Currently, further research is being developed
in order to study the morphological effects of OEA on PA
(Herrera et al., 2014). Moreover, neuroprotective properties of
PEA were reported in a rat model of stroke through MCAo.
PEA treatment (10 mg/kg, 1 h after ischemia and 6 h after
reperfusion) reduced edema, brain infarction, and lesion size,
and improved apoptosis level (assayed by Bax and Bcl-2).
Infiltration of astrocytes was blocked and motor deficits were
reduced (Ahmad et al., 2012b). Similar results were reported after
PEA treatment in mice subjected to an experimental model of
traumatic brain injury (TBI). Controlled cortical impact (CCI)
was performed in adult mice and produced full thickness lesions
in sensorimotor cortex. PEA treatment (10 mg/kg, 1 h after
TBI) could ameliorate secondary damage by reducing lesion size
and blocking infiltration of astrocytes. Moreover, apoptosis level
and neurobehavioral functions were improved. (Ahmad et al.,
2012a).
The effect of PEA on secondary damage induced by SCI was
also tested. SCI was induced in mice by application of vascular
clips to the dura mater via a four-level T5–T8 laminectomy
(compression model). Repeated PEA administration (10 mg/kg,
30 min before, 1 and 6 h after SCI) could significantly ameliorate
the recovery of motor limb function and reduce the degree
of tissue injury and inflammation, pro-inflammatory cytokine
expression, apoptosis, among other biomarkers. This protective
action was exerted through PPARα activation (Genovese et al.,
2008). Further evidence supported the neuroprotective properties
of PEA in SCI. SCI was induced by applying an aneurysm clip to
the spinal cord in mice, thus replicating the persistence of cord
compression (compression model). PEA treatment (10 mg/kg, 6
and 12 h after SCI) was able to diminish mast cell infiltration
and reduce the activation of microglia and astrocytes expressing
CB2 receptor after SCI. These modifications were accompanied
by changes in the expression of neurotrophic factors and in spinal
cord dopaminergic function (Esposito et al., 2011).
Neuroprotective effects of PEA were observed in a
murine model of peripheral neuropathy, which induces
damage of the sciatic nerve by chronic constriction injury
(CCI). Peripheral nerve was rescued from inflammation and
structural derangement after repeated daily treatments with PEA
(30 mg/kg). A reduction of edema and macrophage infiltration,
and an augmentation in myelin sheath and axonal diameter were
observed. In addition, anti-nociceptive effects were registered.
These changes apparently occurred by a PPARα-mediated
mechanism since they were absent in PPARα null mice (Mannelli
et al., 2013).
Finally, neuroprotective properties of OEA (10 mg/kg)
and PEA (10 mg/kg) were recently tested in a murine
model of LPS-induced neuroinflammation. Both pre-treatments
with OEA and PEA (10 min before LPS administration)
could potentiate the hypothermic response after LPS injection,
ameliorate LPS-induced oxidative/nitrosative stress, and reduce
the expression of interleukin-1β (IL-1β), cyclooxygenase-2 (COX-
2), and prostaglandin E2 (PGE2). However, only OEA was able to
reduce brain tumor necrosis factor-α (TNF-α) mRNA and disrupt
LPS-induced anhedonia in a saccharine preference test (Sayd
et al., 2015).
Neuroprotection in Experimental Models
of Neurodegeneration
Exogenous NAEs have exerted neuroprotective activities in
experimental models of Alzheimer disease (AD). PEA reduced
(10 mg/kg) or prevented (30 mg/kg) learning and memory
impairment in mice injected intracerebroventricullarly with
Aβ25–35 peptide (9 nmol). This therapeutic possibility to treat
memory deficits associated with AD was apparently mediated
by activation of PPARα. Besides behavioral improvement, PEA
treatment (once a day, starting 3 h after Aβ25–35, for 1 or
2 weeks) reduced the expression of experimental molecular and
biochemical markers induced by Aβ25–35: lipid peroxidation,
protein nytrosylation, inducible nitric oxide synthase (iNOS)
induction and caspase 3 activation (D’Agostino et al., 2012).
PEA could exert anti-inflammatory and neuroprotective effects
in another experimental model of AD. Adult male rats were
injected intrahippocampally with beta Aβ1–42. PEA treatment
(10 mg/kg, once a day for 7 consecutive days, starting
from the day of the surgery) reduced mnestic deficits and
restored reactive gliosis, amyloidogenesis and tau protein
hyperphosphorylation through PPARα involvement. These
results suggested that PEA could have potential to alleviate the
cognitive symptoms and to modify disease progression (Scuderi
et al., 2014).
Palmitoylethanolamide treatment results in a decreased
Aβ-induced astrocyte activation and improves neuronal survival
via PPARα. Primary rat mixed neuroglial co-cultures and
organotypic hippocampal slices were challenged with Aβ1–
42 and treated with PEA. The findings of this study reveal
the neuroprotective effect of reactive gliosis reduction (Scuderi
et al., 2012). Similar in vitro studies from the same laboratory
were aimed at assessing the effect of exogenous PEA on
the production of pro-inflammatory molecules induced by
Aβ: iNOS, COX-2, nitric oxide, IL-1β, TNF-α, and PGE2.
PEA could blunt the expression and release of all the pro-
inflammatory factors. These effects were attenuated by a PPARα
antagonist, suggesting that the anti-inflammatory properties
of PEA may be mediated by this nuclear receptor (Scuderi
et al., 2011). Moreover, exogenous OEA, PEA, and AEA have
shown an anti-inflammatory response in vitro by preventing the
increase in TNFα, COX-2, and iNOS induced by the pathologic
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form of Aβ. No additive effect was found when the three
NAEs were added together to the cell cultures (Benito et al.,
2012).
Neuroprotective effects of NAEs were encountered in
experimental models of Parkinson disease (PD). Mice were treated
with 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP), which
mimics biochemical and cellular changes that occur in
idiopathic PD. Protection against MPTP-induced loss of
tyrosine hydroxylase (TH) positive neurons in the substantia
nigra was observed in mice treated with PEA (10 mg/kg).
Chronic treatment was initiated 24 h after MPTP injection.
Mice subjected to PEA treatment were also protected against
the alterations of microtubule-associated protein 2a,b, dopamine
transporter and nNos-positive cells in the substantia nigra.
In addition, a reduction in microglial activation and the
number of GFAP-positive astrocytes was observed, and MPTP-
associated motor deficits were reversed. Furthermore, PEA was
apparently protective against neurotoxicity and the ensuing
functional deficits. This neuroprotective effect was exerted
by activating PPARα (Esposito et al., 2012). Neuroprotective
properties of OEA were also tested on experimental models
of PD. OEA exerted cytoprotective effects both in vitro and
in vivo models of 6-hydroxydopamine (6-OHDA)-induced
degeneration of substantia nigra dopaminergic neurons. OEA
could exert a reduction in heme oxygenase-1 (oxidation
marker) and OX6 (reactive microglia marker) in vivo, and
protection against toxicity and cell death in vitro. However,
these effects were U-shaped partial and dose-dependent,
suggesting toxicity due to high drug concentration or an
activation of opposing intracellular pathways by different
OEA doses (Galan-Rodríguez et al., 2009). OEA-mediated
neuroprotection of the nigrostriatal system was supported by
a recent study. The in vivo model consisted of the intrastriatal
infusion of 6-OHDA, which generates Parkinsonian symptoms.
Neurotoxicity and behavioral deficits were less severe in the
animals treated with the highest dose of OEA (5 mg/kg).
In addition, 6-OHDA enhanced heme oxygenase 1 (HO-1)
content was blocked by OEA (5 mg/kg). In vitro, OEA (0.5
and 1 µM) exerted significant neuroprotection on cultured
nigral neurons via PPARα activation (González-Aparicio et al.,
2014).
CONCLUDING REMARKS AND
PERSPECTIVES
Glial cells are apparently responsible for producing NAEs
(Walter et al., 2002; Muccioli and Stella, 2008), which
constitute a homeostatic signaling system in response to
brain damage and inflammation (Esposito and Cuzzocrea,
2013; Skaper et al., 2013). Accordingly, an augmentation
of NAEs levels has been reported in brain aging (Pascual
et al., 2014), Aβ-induced astrogliosis (Scuderi et al., 2011),
neurodegeneration (Kallendrusch et al., 2010), SCI (Garcia-
Ovejero et al., 2009), stroke (Schäbitz et al., 2002; Berger et al.,
2004), and cerebral ischemia (Natarajan et al., 1986; Franklin
et al., 2003). The Autacoid Local Injury Antagonism (Skaper
et al., 1996) and the entourage effect (De Petrocellis et al.,
2001; Cravatt and Lichtman, 2002; Ross, 2003; Bradshaw and
Walker, 2005; Re et al., 2007; Liput et al., 2014) were proposed
as mechanisms of NAEs homeostatic functions. However, in
some pathological scenarios, NAEs endogenous synthesis is
inadequate to control the inflammatory cascade (Skaper et al.,
2013). When there is chronic non-resolving inflammation,
dysfunctional reactive gliosis becomes detrimental and glial
activity might not be beneficial any longer (Pekny and Pekna,
2015). Therefore, exogenous NAEs may exert neuroprotective
effects by down-regulating astrocytes (Ahmad et al., 2012a,b;
Scuderi et al., 2012, 2014), microglia (Galan-Rodríguez et al.,
2009), or both microglia and astrocytes (Esposito et al., 2011,
2012). In this sense, glia constitutes a target for exogenous
NAEs (Scuderi et al., 2013; Skaper et al., 2013). Moreover,
inhibition of endogenous NAEs degradation could represent a
complementary therapeutic approach for neuroinflammation.
Potential selective N-acylethanolamide-hydrolyzing acid amidase
(NAAA) inhibitors have shown anti-inflammatory effects
(Solorzano et al., 2009; Saturnino et al., 2010; Li et al., 2012;
Yamano et al., 2012). This fact supports the involvement
of NAEs in the control of inflammation (Petrosino et al.,
2010). However, future research should attempt to clarify the
role of glial cells in brain injury, and their interaction with
NAEs.
Neuroprotection exerted by exogenous PEA and OEA was
observed in several in vivo and in vitro models of brain
injury and neurodegenerative diseases (Genovese et al., 2008;
Galan-Rodríguez et al., 2009; Esposito et al., 2011, 2012;
Scuderi et al., 2011, 2012, 2014; Ahmad et al., 2012a,b;
Benito et al., 2012; D’Agostino et al., 2012; Zhou et al.,
2012; Mannelli et al., 2013; González-Aparicio et al., 2014;
Sayd et al., 2015). However, the entourage effect was not
referred as a mechanism of neuroprotection. In addition, a
group of researchers has studied this issue in particular. PEA-
mediated neuroprotective effects in dentate gyrus granule cells
in excitotoxically lesioned OHSCs (Koch et al., 2011) were
not exerted by AEA (Kreutz et al., 2007). Therefore, the
entourage hypothesis could not explain PEA neuroprotective
action, which was actually mediated by PPARα activation (Koch
et al., 2011).
Peroxisome proliferator-activated receptor-α appears as a
crucial site at which PEA and OEA generate their neuroprotective
actions. Exogenous PEA and OEA have repeatedly exerted
neuroprotective effects by activating the anti-inflammatory
nuclear receptor PPARα (Lo Verme et al., 2005; Sun et al.,
2007; Genovese et al., 2008; Scuderi et al., 2011, 2012, 2014;
D’Agostino et al., 2012; Esposito et al., 2012; Zhou et al.,
2012; Mannelli et al., 2013; González-Aparicio et al., 2014).
Additionally, endogenous PEA and OEA have demonstrated
protective effects via PPARα in activated cultured primary rat
astrocytes subjected to Aβ accumulation (Scuderi et al., 2011)
In fact, a recent hypothesis proposes that PPARs play a crucial
role on metabolic and inflammatory compensation of astrogliosis
and may interact with ligands on different metabolic pathways
in order to supply energy to the neurons (Iglesias et al.,
2016).
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Moreover, some studies on neuroprotective effects of
exogenous PEA and OEA revealed a co-occurrence between
PPARα activation and down-regulation of glia (Esposito et al.,
2012; Scuderi et al., 2012, 2014). Additionally, it was hypothesized
that PEA-mediated PPARα activation could reduce significantly
the number of microglial cells and counteract secondary neuronal
damage of dentate gyrus granule cells in excitotoxically lesioned
OHSCs (Koch et al., 2011). Further studies might help to
elucidate whether NAEs-mediated PPARα activation is capable
of counteracting glial activation.
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